Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IC14 in Rapidly Progressive ALS
NCT03474263Phase 2Withdrawn
- Sponsor
- Implicit Bioscience
- Start
- Sep 2019
- Primary completion
- Apr 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atibuclimab in amyotrophic lateral sclerosis (ALS), sponsored by Implicit Bioscience. Planned start Sep 2019; status: withdrawn.
02
Drugs
atibuclimab
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03474263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03474263.